Abstract | A fundamental function of the intestinal epithelium is to act as a barrier that limits interactions between luminal contents such as the intestinal microbiota, the underlying immune system and the remainder of the body, while supporting vectorial transport of nutrients, water and waste products. Epithelial barrier function requires a contiguous layer of cells as well as the junctions that seal the paracellular space between epithelial cells. Compromised intestinal barrier function has been associated with a number of disease states, both intestinal and systemic. Unfortunately, most current clinical data are correlative, making it difficult to separate cause from effect in interpreting the importance of barrier loss. Some data from experimental animal models suggest that compromised epithelial integrity might have a pathogenic role in specific gastrointestinal diseases, but no FDA-approved agents that target the epithelial barrier are presently available. To develop such therapies, a deeper understanding of both disease pathogenesis and mechanisms of barrier regulation must be reached. Here, we review and discuss mechanisms of intestinal barrier loss and the role of intestinal epithelial barrier function in pathogenesis of both intestinal and systemic diseases. We conclude with a discussion of potential strategies to restore the epithelial barrier. NATURE REVIEWS | GASTROENTEROLOGY & HEPATOLOGY VOLUME 14 | JANUARY 2017 | 9
An essential function of the intestinal mucosa is to act as a barrier between luminal contents and the under lying immune system. The term 'intestinal barrier' is increasingly used to refer to the mucus layer or the underlying mucosal immune system, and although each of these mucosal components provides a type of barrier, the physical epithelial barrier confers the property of selective permeability to the intestinal mucosa. The term 'intestinal barrier function' will therefore be used here to refer to the ability of the intestinal epithelium to restrict free exchange of water, ions and macro molecules between the intestinal lumen and the underlying tissues. Intestinal permeability is the inverse of intestinal barrier function, and because the intestinal mucosa must simul taneously promote nutrient and water transport while serving as a protective barrier, neither property is abso lute. Instead, intestinal barrier function depends on a variety of mucosal structural components that are tightly regulated in homeostasis and during disease [1] [2] [3] . The luminal surface of the intestinal mucosa is lined by a hydrated gel, composed of mucins secreted by gob let cells [4] [5] [6] . This layer prevents large particles and intact bacteria from coming into direct contact with the under lying epithelium. The importance of the mucus layer is emphasized by the observations that mucin structure is markedly altered in active enterocolitis and that knockout mice lacking the Muc2 gene, which encodes the major component of intestinal mucin, develop spontan eous colitis 7 . However, the mucus layer does not establish a substantial barrier to transmucosal water or solute flux; that job falls to the epithelial monolayer, which is the primary determin ant of mucosal barrier function 8 . The apical surface of the epithelium forms a single, continu ous border as a result of the precise alignment of abutting cells. In an intact epithelium, this surface restricts passage of most hydrophilic solutes. However, to limit trans mucosal flux, the paracellular space must also be sealed. The task of regulating paracellular transport is achieved by a series of intercellular junctions.
The apical junctional complex
From an apical to basal direction, the intercellular junc tions are the tight junction (ZO; zonula occludens), adherens junction (zonula adherens) and desmosome (FIG. 1) . Together these three types of intercellular junc tions comprise the apical junctional complex Adherens junctions and desmosomes provide the adhesive forces necessary for maintenance of cell-cell interactions. The most wellknown component of the adherens junctions are the cadherins -single spanning transmembrane proteins that interact homotypically with the extracellular portion of cadherins on adjacent cells 12 . On the cytoplasmic face, cadherins interact directly with p120 catenin and βcatenin, which in turn inter act with αcatenin 13 . Among other functions, αcatenin regulates perijunctional actin assembly, which provides further strength to these structures 14, 15 . In addition, the adherens junction is necessary for efficient tight junction assembly, a function that in vitro studies have attributed to both epithelial cadherin (Ecadherin) and αcatenin 16, 17 . The tight junction is the primary determinant of para cellular permeability. When viewed using transmission electron microscopy, the tight junction seems to elimin ate the intercellular space at socalled 'kissing points, ' and freezefracture electron microscopy clearly shows that tight junctions consist of a series of anastomosing strands 9, 18 . Results from a study using direct rapid freez ing methods suggested that tight junction strands might exist as pairs of inverted micelles formed by the fusion of the outer leaflets from plasma membranes of abutting cells 19, 20 ; however, this model has largely been abandoned with the discovery of tightjunctionassociated structural and regulatory proteins 19, 20 . Immunoelectron micro scopy has demonstrated transmembrane proteins within tight junction strands 21 . Multiple subsequent studies have shown that tight junction proteins reside in cholesterol rich, detergent insoluble lipid domains [22] [23] [24] . These find ings have led to speculation that dynamic fusion and fission of lipidbased tight junction strands might account for selective permeability (a detailed review con sidering the lipidic nature of tight junctions can be found elsewhere 20 ). Specialized lipids and proteins are probably necessary components of the tight junction barrier; how ever, to date, far more work has been done to identify the structure and regulation of tight junction proteins.
Tight junction proteins can be broadly separated into transmembrane proteins, cytosolic plaque (scaffolding) proteins and regulatory proteins. Of the transmembrane tight junction proteins, the tetraspanning claudins are the most important, as the extracellular domains of clau dins on adjacent cells form pores to regulate tight junc tion ion selectivity 25 . A seminal study determined that expression of a single claudin family member, claudin2, is largely responsible for differences in transepithelial resistance between two clones of Madin Darby canine kidney cells 26 . Subsequent analyses have shown that claudin 2driven decreases in epithelial barrier func tion are due to increases in paracellular ion conductance without accompanying alterations in flux of larger mol ecules [27] [28] [29] . Data showing that individual claudin2based channels are dynamically gated suggests that altering the opening and closing of claudin2 pores is a targetable process for barrier modulation 28 . An alternative poten tial method of inhibiting claudin2 function comes from the observation that prevention of caseinkinase2 mediated occludin phosphorylation promotes assembly of a tight junction complex that blocks claudin2 pore function, thereby reversing IL13induced barrier loss in vitro 30 . However, such therapies must be approached with caution, as transtight junction Na + recycling, from the lamina propria into the lumen, is necessary to sup port critical transcellular vectorial transport processes such as nutrient absorption [31] [32] [33] . The ZO family of proteins (ZO1, ZO2 and ZO3, encoded by the genes TPJ1, TPJ2 and TPJ3, respec tively) are multidomain scaffolding proteins that interact directly with transmembrane tight junction proteins such as claudins and the tight junctionassociated MARVEL protein (TAMP) family, which includes occludin 21, [34] [35] [36] . ZO proteins also interact with the actin cytoskeleton and a variety of actin regulatory elements 37 . The ZO proteins have many similar structural domains, which has led to the hypothesis that they serve similar functions 37, 38 . However, these proteins must also have unique func tions as knockout of either Tjp1 or Tjp2 genes results in embryonic lethality in mice 39, 40 . Studies in humans have discovered two distinct pathogenic TJP2 mutations 40, 41 . The first mutation impairs ZO2 binding to claudins and results in an incompletely penetrant familial hyperchola naemia, which presents with elevated serum bile acid levels, pruritus and fat malabsorption 41 . The second dis covered mutation in TJP2 encodes a truncated protein and is associated with severe cholestatic liver disease that presents early in life and frequently requires liver trans plantation 42 . In this case, claudin1, but not claudin2, fails to localize to tight junctions within canalicular and cholangiocyte membranes. Interestingly, a study of mice lacking claudin2, which forms a para cellular Na + and water channel, found that these mice generated more concentrated bile and were susceptible to gallstone dis ease, suggesting that claudin2mediated paracellular water and/or Na + flux contributes to bile hydration 43 . The ability of this truncated ZO2 to support human life, while Tjp2 gene knockout is lethal in mice, suggests that the shortened protein is partially functional, possibly via oligomerization with ZO1. Alternatively, the data might
Key points
• The intestinal epithelium is a dynamic cellular layer that serves as a barrier between luminal contents and the underlying immune system while simultaneously supporting water, nutrient and ion transport • Tight junctions are the primary determinants of barrier function in intact epithelia and are composed of a complex network of transmembrane and cytosolic proteins accompanied by cytoskeletal and regulatory proteins • Two distinct pathways -termed pore and leak -regulate paracellular flux in intact epithelia whereas the unrestricted flux pathway is the dominant route across ulcerated or denuded epithelia • Reduced intestinal epithelial barrier function is associated with a variety of gastrointestinal and systemic diseases, including IBD and graft versus host disease, respectively, but is insufficient to cause disease in the absence of other insults • Experimental evidence suggests that barrier defects contribute to IBD, as mouse models demonstrate that increased paracellular permeability accelerates experimental colitis and that preservation of tight junction barrier function delays disease progression • Although no currently available therapeutics specifically modulate epithelial barrier function, promising approaches to target the pore, leak, and unrestricted pathways are being investigated indicate species differences in the redundancy between ZO1 and ZO2. In either case, these data highlight the importance of tight junction proteins in homeostasis and prevention of gastrointestinal diseases. Although barrier function has not been measured in patients with either TJP2 mutation, the differences in localization of claudin proteins to tight junctions implies that, as in the claudin2knockout mouse, altered epithelial barrier function might result in hepatobiliary disease 41, 42 . This finding is consistent with many other studies that have linked intestinal barrier dysfunction to hepatitis 44, 45 .
Paracellular permeability pathways
The tight junction barrier exhibits both size and charge selectivity with two distinct routes across an intact epi thelial monolayer, termed the 'pore' and 'leak' pathways 3, 8 ( FIG. 2) . The pore pathway refers to a highcapacity, sizeselective and chargeselective route, whereas the leak pathway is a lowcapacity pathway that has more limited selectivity 3, 8 . Pore pathway permeability seems to be determined primarily by the subset of claudins expressed, whereas leak pathway permeability can be regulated by ZO1, occludin and myosin light chain kinase (MLCK) 8, 30, 46 . At sites of epithelial damage, such as erosions and ulcers, tight junctions are lost and therefore cannot contribute to local barrier function. Instead, luminal contents cross the intestinal barrier by a third pathway, termed the 'unrestricted' pathway. As its name suggests, the unrestricted pathway is highcapacity and nonselective with respect to solute size and charge. Large proteins and even whole bacteria can cross the unrestricted pathway, which partially explains the severe disease initiated by epithelial damage. In the setting of extensive epithelial injury, such as that occurring in humans with necrotizing enterocolitis or rodents treated with dextran sulfate sodium (DSS), the unrestricted pathway is often unsealed and is the predominant route of transmucosal flux [47] [48] [49] . However, during homeostasis and less active inflammatory disease, the epithelium is generally intact and barrier function primarily reflects flux across the paracellular pore and leak pathways 29, 48, 50 .
Regulation of the epithelial barrier Homeostatic regulation. During homeostasis, the intes tinal epithelium is a highly dynamic structure and is estimated to completely selfrenew every 4-7 days 2, [51] [52] [53] . Stem cells reside in the intestinal crypts where they pro liferate, and daughter cells differentiate as they migrate up the crypt-villus axis to be ultimately shed into the intestinal lumen. This constant turnover presents an opportunity for potential breaches in the epithelial barrier with concomitant increases in flux across the unrestricted pathway. However, both shedding events and oligocellular wounds are accompanied by the for mation and subsequent contraction of a multicellular actomyosin purse string, which drives tight junction expansion to the basal surface of the extruded cell to rapidly reestablish the contiguous epithelium and tight junction barrier [54] [55] [56] . The most studied example of physiological regula tion of the tight junction barrier is that which occurs upon activation of sodium-glucose cotransport [57] [58] [59] [60] [61] . This cotransport leads to activation of epithelial MLCK as well as development of a transepithelial osmotic gradient. MLCK activity increases paracellular perme ability via the sizeselective pore pathway, and in the setting of an osmotic gradient, this increased perme ability enables paracellular absorption of small nutrients (such as glucose) via solvent drag 57, 59, [61] [62] [63] [64] .
Pathophysiological regulation of leak and pore pathways. The pore and leak pathways are also regulated in response to pathophysiological stimuli. Perhaps the most wellstudied example is flux across the pore pathway due to IL13induced increases in claudin2 expression 29, 65 . Notably, IL13 is not the only immunological regulator of claudin2 expression and pore pathway permeability, as IL6, IL4, IL9 and TNF have also been reported to induce claudin2 expression [65] [66] [67] [68] [69] [70] [71] . Although one study suggested that IL13 causes barrier loss by inducing claudin2 expression as well as increasing apoptosis and inhibiting wound healing 65 , both in vitro and in vivo studies using lower doses of IL13 have shown claudin2 upregulation and claudin2dependent pore pathway activation in response to IL13 exposure without associ ated increases in leak or unrestricted pathway flux 29 .
Nature Reviews | Gastroenterology & Hepatology This finding is consistent with biophysical studies demonstrating that claudin proteins such as claudin2 form paracellular channels with exquisite size and charge selectivity, and both closed and open states, sim ilar to transmembrane ion channels 28, [72] [73] [74] . Interestingly, crypt but not surface epithelial cells express claudin2 under normal conditions, consistent with the increased paracellular permeability of the former [75] [76] [77] . The cytokine TNF has also been shown to regulate tight junction function, and the clinically relevant role of TNF in IBD pathogenesis is clearly demonstrated by the efficacy of antiTNF antibodies, which reduce dis ease severity and restore intestinal barrier function 78, 79 . Repair of epithelial barrier function following antiTNF therapy might reflect mucosal healing in the setting of a dampened immune system. However, preclinical stud ies have shown that TNF signalling also modulates tight junction barrier function directly 48, [80] [81] [82] [83] . This relationship was first recognized in vitro by the association between barrier loss and increased myosin light chain (MLC) phosphoryl ation in response to TNF 80 . Pharmacological inhib ition of MLCK activity in vitro rapidly reduced MLC phosphoryl ation and restored tight junction barrier func tion 80 . Using both pharmacological and genetic methods of MLCK inhibition, TNFinduced MLC phosphoryl ation and tight junction barrier dysfunction was shown to be required for diarrhoea in vivo 84 . Subsequently, TNF was found to also upregulate claudin 2 expression, thereby enhancing pore pathway flux 68 . However, this process only occurred after many hours of TNF treat ment in contrast to the rapid regulation of MLCK tran scription 85 , and is therefore best considered a secondary phase of TNFinduced barrier regulation that might be indirect. Notably, the expression of constitutively active MLCK (CAMLCK) within the intestinal epithelium also upregulated claudin2 expression in vivo, despite the absence of overt disease 29, 48, 86 . Further studies demonstrated the contribution of tight junction barrier loss to the pathogenesis of experi mental colitis (discussed in the next section) 48, 86 . TNF diminishes epithelial barrier function largely by indu cing occludin internalization via a caveolin1 dependent process 87 , which was demonstrated in vivo as either pharma cological or genetic inhibition of caveolin1 function limited both occludin internalization and TNFmediated diarrhoea 87 . Furthermore, occludin overexpression in intestinal epithelial cells limited TNF induced barrier loss and prevented TNFinduced diar rhoea 87 . This finding reflects the relative preservation of tight junction occludin pools, despite MLCK activation, in mice that overexpress occludin 87 . These data indi cate that the removal of occludin from tight junctions, rather than some other component, leads to barrier loss. In vitro studies have corroborated this finding by show ing that occludin depletion results in decreased barrier function and that occludindeficient intestinal epithe lial cell monolayers are resistant to further TNFinduced barrier loss 88, 89 . Given the greater paracellular perme ability of crypt epithelium relative to surface epithelium, it is notable that crypt epithelia have substantial intra cellular occludin pools in the absence of inflammatory stimuli, whereas surface epithelia do not [75] [76] [77] . Subsequent domain analyses suggest that barrier regulation by occludin requires direct interactions between occludin Nature Reviews | Gastroenterology & Hepatology Figure 2 | Three distinct paracellular epithelial permeability pathways are disrupted during disease pathogenesis. During homeostasis (left) there is little underlying mucosal immune activity and the 'leak' and 'pore' pathways, regulated by tight junctions, define intestinal permeability. In the presence of an intact epithelium, cellular membranes seal the 'unrestricted' pathway, which is independent of tight junctions. During disease pathogenesis (right), increased mucosal immune activation leads to TNF and IL-13 production, which can cause increased permeability across the leak and pore pathways, respectively. TNF enhances leak pathway permeability by both increasing myosin light chain kinase (MLCK) transcription and activity at the tight junction and causing occludin endocytosis. Pore pathway permeability is increased by IL-13-dependent claudin-2 upregulation. As inflammatory disease progresses, epithelial apoptosis occurs and permeability across the high-capacity, charge and size-nonselective unrestricted pathway dominates. Upon removal of inflammatory stimuli, the epithelium regenerates to seal the unrestricted pathway and restore permeability dependent on tight junctions. Multiple therapeutic approaches targeting the intestinal epithelial barrier have been proposed (centre). These approaches aim to either inhibit initiation and progression of disease through immunosuppression or inhibition of barrier loss dependent on tight junctions, or through restoration of epithelial barriers after disease onset by inhibiting inflammation or promoting epithelial regeneration. EGF, epidermal growth factor; IL-13R, IL-13 receptor; TNFR2, TNF receptor 2.
and ZO1 (REF. 88 ). Unlike claudin channels that represent the structural pathway route of pore pathway conduct ance, the precise sites of paracellular leak pathway flux are not yet defined. The observation that overexpression of the occludinrelated protein tricellulin reduces leak pathway conductance without affecting the pore path way suggests that tricellular junctions might be the sites of leak pathway flux 90, 91 . Interestingly, tricellulin is found at both tricellular and bicellular tight junctions, rather than only at the former, after occludin knockdown 88, 92 . This finding raises the possibility that redistribution of tricellulin following occludin endocytosis contributes to TNFinduced barrier loss 88, [91] [92] [93] . However, neither intes tinal barrier defects nor intestinal disease have been described in humans or mice with tricellulin muta tions [94] [95] [96] . Humans with occludin mutations have not yet been identified, but occludinknockout mice, which are deaf, display tricellulin redistribution to bicellular tight junctions within the inner ear 97 and have been reported to lack intestinal barrier defects 98, 99 . Although the leak and pore pathways represent distinct routes across the paracellular barrier, the two pathways are often affected in parallel. For example, in patients with IBD and in the SAMP1/YitFc mouse model of colitis, claudin2 mRNA expression is increased and occludin expression is decreased, indicating that both leak and pore pathways are activated 65, 100 . Mechanistic interplay between the pathways was demonstrated using mice expressing a CAMLCK within the intes tinal epithelium 29 . Colonic mucosae of these mice dis played increased cation selectivity that could not be explained by MLCKdependent increases in leak path way flux. Instead, in vivo responses to MLCK activation were shown to result in mucosal immune activation, enhanced IL13 expression, and subsequent increases in claudin2 expression that led to increased cation flux across the pore pathway 29 .
Intestinal barrier function and disease Impaired intestinal barrier function has been associated with an increasing variety of diseases -both intesti nal and systemic (TABLE 1) -leading to the popular ization of the catchall diagnosis of socalled leaky gut syndrome [101] [102] [103] . The vast majority of these associations are merely correlative, but experimental evidence relat ing barrier dysfunction to disease pathogenesis exists in some cases, including IBD and coeliac disease 103 . Some bacterial pathogens are also capable of reducing tight junction barrier function including MLCK activ ation during enteropathogenic Escherichia coli infec tion 80, 104, 105 , direct interactions with specific claudins by Clostridium perfringens enterotoxin 106, 107 and Rho GTPase inhibition by C. difficile toxins 108, 109 .
IBD.
The association between intestinal barrier dys function and intestinal disease was first recognized by studies using an ex vivo approach that documented increased permeability in active IBD, in both ulcerated and nonulcerated epithelia [110] [111] [112] . Subsequent studies revealed that tight junction function, ultrastructure and protein composition are altered in patients with active IBD 71, 113 . Expression and activity of MLCK as well as expression of claudin2 are also increased in active IBD, suggesting that tight junction dysregulation might have a pathogenic role in IBD before epithelial ulcer ation 114, 115 . Consistent with this idea, intestinal perme ability has been reported as a fairly sensitive prognostic indicator of relapse to active disease in patients with Crohn's disease during clinical remission 116, 117 . These results have been corroborated by a study of 43 patients with Crohn's disease, which also reported increased levels of the intestinal inflammation marker, faecal calprotectin, before relapse 118 . This finding blurs the exact role of intestinal barrier dysfunction in relapse because, as indicated by in vitro and in vivo studies, subclinical levels of inflammation might be respon sible for increased permeability. Consistent with this hypothesis, inflammatory cytokine exposure is associ ated with increased epithelial cell turnover in vivo 55 , and one clinical study using confocal laser endomicroscopy reported that increased epithelial shedding and leak age of fluorescein dye across the intestinal epithelium in patients with IBD correlated directly with risk of relapse within 1 year 119 . Despite this finding, it is worth noting that the fluorescein dye flux observed was into the lumen, suggesting that barrier defect might result in local fluid efflux and, therefore, might enable only limited passive transport of luminal materials into the mucosa. Furthermore, many studies have shown relative maintenance of barrier function at sites of epithelial shedding 55, 56, 120 . The contribution of increased intestinal perme ability to disease pathogenesis was first proposed with the realiza tion that a subset of firstdegree relatives of patients with Crohn's disease also display increased intestinal permeability 121 . Some of these individ uals might also have an altered microbial metabolic state 122, 123 . Although firstdegree relatives do have an increased risk of developing Crohn's disease relative to the overall population, it remains to be determined if the subset with increased intestinal permeability are at greater risk than those without increased intestinal permeability. However, interestingly, relatives with increased intestinal permeability tend to carry a specific disease associated poly morphism of NOD2 (previously known as CARD15), which encodes a protein involved in bacterial recognition 124 . Although interesting in the context of disease, these studies also demonstrate that increased intestinal permeability alone is insufficient to cause overt clinical disease, as many healthy first degree relatives also harbour this deficit 121, 125 . Nevertheless, one case report identified a firstdegree relative who had increased intestinal permeability before clinical presentation of Crohn's disease, suggesting a potential patho genic role for intestinal barrier function in IBD 126 . This single case report must, however, be interpreted with caution given the individ ual's already increased risk of developing IBD. Furthermore, as noted, no studies have assessed longterm disease risk in first degree relatives with increased intestinal permeability. However, a range of exciting data from experimental mouse models have provided evidence supporting the idea that intestinal barrier loss can be one compo nent that contributes to a multifactorial mechanism of IBD pathogenesis 48, 49, 86, 127 . Coeliac diseae. In simple terms, coeliac disease becomes apparent when genetically susceptible individuals ingest glutencontaining foods. Luminal and brush border enzymes digest gluten into gliadin, an alcohol soluble peptide. In patients with coeliac disease, gliadin drives mucosal immune activation by incompletely defined mechanisms that result in intestinal inflammation and epithelial damage 128 . To accomplish this step, gliadin must cross the epithelial barrier. Although the route by which gliadin is passed from the lumen to the lamina propria is controversial (transcellular or paracellular route), diminished intestinal barrier function is pro posed to have a pathogenic role in coeliac disease. Support for the hypothesis that barrier loss contributes to coeliac disease pathogenesis first came from obser vations that intestinal permeability to nonmetabolizable sugars is increased during active disease and decreases to normal ranges after consumption of a glutenfree diet for several months 129 . Conversely, gluten challenge in patients with coeliac disease who have been on a glutenfree diet can increase intestinal permeability 129 . Later studies found that intestinal permeability posi tively correlates with disease activity and is increased in both patients with coeliac disease and their healthy relatives 130, 131 . Moreover, improvements in barrier func tion have been shown to precede histological evidence of disease improvement after initiation of a glutenfree diet 132 , and have even been reported in patients with diarrhoeapredominant IBS after introduction of a glutenfree diet 133 . Animal models of coeliac disease include a sub set of Irish setter pups, which are gluten sensitive 134 . Similar to patients with coeliac disease, glutensensitive Irish setter pups display glutendependent increases in intestinal permeability that precede histological entero pathy 134 . These observations are supported by multiple studies showing increased intestinal permeability upon gluten exposure in glutensensitive HLADQ8 trans genic mice 135, 136 . Each of these results can potentially be explained by immune signalling to intestinal epithelia that results in increased permeability. Consistent with this idea, removal of the immune stimulus (that is, gliadin) restores intestinal barrier function 129 . However, in vitro studies indicate that gliadin might have a direct effect on the intestinal epithelium, as exposure to gliadin and gliadin peptides produces a substantial reduction in barrier function of confluent intestinal epithelial cell (IEC6) monolayers 137 . A similar result was reproduced using the human intestinal epithelial cell line Caco2, and in this study, sizeselectivity of gliadininduced barrier defects was assessed by measuring flux of both 4 kDa and 70 kDa FITCdextran across treated mono layers 138 . This study revealed that gliadinexposed Caco2 monolayers were considerably more permeable to small (4 kDa) but not large (70 kDa) dextrans, indicat ing an increase in leak pathway flux without increased flux across the unrestricted pathway 138 . The mechanism for gliadinmediated reductions of epithelial barrier function has been proposed to involve upregulation of zonulin, a putative regulator of tight junction permeability. Zonulin expression is increased in patients with active coeliac disease, and a zonulin antagonist, larazotide acetate (AT1001), inhib its gliadin induced reductions in epithelial permeability in vitro and in vivo 139, 140 . Unfortunately, although some clinical benefit has observed, trials of larazotide have not demonstrated reductions in intestinal permeability 141 .
Other mechanisms of barrier loss in coeliac disease might reflect polymorphisms in myosinIXb, which have been linked to coeliac disease 142, 143 . MyosinIXb is a Rho GTPaseactivating protein (GAP) that plays a part in actin remodelling 144 . The myosinIXb polymorphisms linked to coeliac disease are within the Nterminal portion of myosinIXb, the region of the protein that confers RhoGAP activity 144, 145 . However, studies of myosinIXb variants in additional populations have failed to demonstrate an association with coeliac dis ease 146, 147 . These conflicting results might be due to population differences, unidentified environmental cofactors, or falsepositive or falsenegative results. Nevertheless, some support for a pathogenic role of myosinIXb polymorphisms comes from studies link ing the variants to Crohn's disease and ulcerative coli tis [148] [149] [150] .
Although it remains to be tested if the identified myosinIXb variants are pathogenic, the association of polymorphisms in a single protein with multiple disease entities underscores the hypothesis that common cellu lar mechanisms might underlie multiple inflammatory diseases. In vitro studies using Caco2 monolayers have shown an essential role of myosinIXb in intestinal epi thelial wound closure, tight junction protein localiza tion and epithelial barrier function at steady state 151 . All of these data suggest that myosinIXb might have an important role in maintaining the barrier by regulating both the tight junction and epithelial repair. Although intestinal permeability has not been studied in patients carrying myosinIXb polymorphisms, it is interesting to speculate that these variants might increase dis ease susceptibility by enhancing flux across both tight junction leak and unrestricted pathways. Indeed, myo sinIXbknockout mice were shown to have diminished epithelial barrier function, characterized by increased 40 kDa dextran flux 152 . These observations are prob ably explained by increased rates of epithelial apoptosis. However, intestinal epithelia from myosinIXbknock out mice also display increased subapical phosphoryl ated MLC and reduced ZO1 recruitment to tight junctions 152 . Other studies have identified changes in claudin protein expression that might also affect flux across the tight junction pore pathway 153, 154 . Thus, as in IBD, all three flux pathways probably contribute to permeability increases in coeliac disease.
One final factor that might affect transmucosal flux in coeliac disease is the reduction in mucosal surface area as a result of villous blunting, which is often associ ated with reactive crypt hyperplasia 128 . Together, these events result in a skewing of the crypt:villus surface area ratio. The leak pathway of crypt tight junctions is far more permeable than in the villus [75] [76] [77] , which probably increases leak pathway flux. However, pore pathway flux might also be reduced as a result of the overall loss of surface area. These changes explain the increased permeability to lactulose (as it is a leak pathway probe), decreased flux of the pore pathway probe mannitol and increased lactulose:mannitol ratio in coeliac disease 130, 155, 156 .
Mouse models of intestinal barrier function in disease.
A variety of mouse models have led to a more sophis ticated understanding of the contribution of intestinal barrier function to inflammatory diseases. The critical role of epithelial barrier function in homeostasis was demonstrated in chimeric mice expressing a dominant negative Ncadherin cytoplasmic tail within intestinal epithelia 157, 158 . ECadherinmediated interactions were disrupted in intestinal epithelial cells expressing the Ncadherin tail, which resulted in aberrant epithelial differentiation, chronic active inflammation and dys plasia 157 . A histologically similar inflammatory process characterized by erosions and ulcerations was reported in mice lacking intestinal epithelial p120catenin, which display marked Ecadherin downregulation owing to enhanced degradation in the absence of p120catenin 159 . Mice with a targeted, conditional Ecadherin deletion within intestinal epithelium have also been generated 160 . These mice display altered differentiation patterns, enhanced epithelial apoptosis, bloody diarrhoea and impaired bacterial defense 160 . Disease in each of these models probably reflects marked disruption of tight junctions secondary to adherens junction disassembly, aberrant epithelial differentiation and epithelial apop tosis, and can therefore be considered a model of dis ease driven, at least partially, by unrestricted pathway defects. This disruption might be a component of IBD pathogenesis, but it is unlikely to reflect a primary mech anism in disease presenting after the neonatal period. Nevertheless, it is interesting that polymorphisms near the Ecadherinencoding gene CDH1 have been linked to ulcerative colitis 161 . Similar to human patients [162] [163] [164] , colitis development in IL10 / mice 165, 166 is highly variable in penetrance, age of onset and severity. Environmental stimuli and genetic factors, including both targeted changes and strain specific differences, contribute to the observed vari ation 166, 167 . Moreover, enteric bacteria are necessary for colitis onset, as germfree IL10 / mice do not develop dis ease and antibiotic treatment can attenuate colitis 166, 168, 169 , which correlates with observations of altered microbial communities in patients with IBD 170 . Although the pri mary defect in IL10deficient mice is immune, intesti nal barrier defects are present before clinical evidence of disease onset and do not develop under germfree conditions 168 . However, whether increased intestinal permeability is a key pathogenic component of colitis in IL10 / mice or simply an early marker of mucosal injury is unclear from these data. Several studies suggest that the former might be true. First, it is now well appreciated that the NSAID piroxicam can promote disease develop ment in IL10 / mice 171 . Given that NSAIDs are known to result in epithelial damage, NSAID treatment prob ably provokes disease by increasing flux across the unrestricted pathway. Similarly, administration of a zonulin agonist enhanced intestinal permeability and modestly increased disease severity in IL10 / mice 172 . Conversely, a zonulin antagonist reduced intestinal per meability and disease severity in IL10 / mice 173 . Although the mechanism of action of these agents (including their specificity) is unclear, these data do suggest that modu lating intestinal permeability can affect colitis genesis in IL10deficient mice.
Mouse models with targeted apical junctional com plex defects might shed light on the role of the tight junctionmediated barrier in colitis development and progression. For example, mice lacking junctional adhesion moleculeA (JAMA), which facilitates tight junction assembly and leukocyte transmigration, dis play altered claudin protein expression and increases in epithelial apoptosis, proliferation and migration even in the absence of clinically apparent disease 127 . JAMA deficient mice are also hypersensitive to DSS injury 127 . This observation might indicate that JAMA expression is either protective against intestinal epithelial damage or enhances regenerative capacity, but could also reflect the inability of knockout mice to mount an adequate response to DSS injury given the preexisting chronic epithelial damage. Importantly, JAMA is expressed in many tissues and a specific role for intestinal epithelial JAMA has not been assessed. Notably, however, intes tinal epithelial, but not endothelial, JAMA expression is downregulated in patients with IBD 127 .
A more precisely targeted model has taken advan tage of the physiologically and pathophysiologically relevant tight junction regulator MLCK to increase intestinal paracellular permeability. In this model, CAMLCK was expressed specifically within intesti nal epithelia 86 . This perturbation increased intestinal paracellular permeability without affecting epithelial maturation, proliferation or turnover, much like the subset of healthy firstdegree relatives of patients with Crohn's disease with increased intestinal permeability 86 . CAMLCK transgenic mice mature normally without developing spontaneous disease, but they do exhibit subclinical immune activation with type 1 T helper (T H 1) cell polarization 86 . Furthermore, when chal lenged by adoptive transfer of effector T cells, disease onset is accelerated, severity is worsened and overall survival is reduced relative to nontransgenic litter mates 86 . These experimental data are consistent with patient data indicating barrier dysfunction alone is insufficient to cause clinically detectable disease, and also provide direct evidence that isolated tight junction dysfunction can contribute to disease pathogenesis in susceptible hosts. As discussed earlier, the CAMLCK induced increase in leak pathway permeability also results in claudin2 upregulation and enhanced pore pathway flux 29 . A subsequent study investigated the interplay between immune activation, TNF signalling, intesti nal epithelial MLCK expression and intestinal barrier function using an immunemediated adoptive trans fer colitis mouse model 48 . Similar to human disease 115 , intestinal epithelial MLCK expression increased as colitis progressed 48, 115 . In mice, this finding was accom panied by increased intestinal epithelial transcription and expression of TNFR2 (TNF receptor 2), which had been shown to mediate TNFinduced increases in MLCK transcription in vitro 83 . Consistent with this finding, TNFR2deficient mice failed to upregulate MLCK expression or MLC phosphorylation within intestinal epithelium 48 . By contrast, deletion of TNFR1, which often regulates signalling in immune cells, had no effect on intestinal epithelial MLCK expression or activity 48, 83 . Furthermore, mice lacking either TNFR2 or epithelial MLCK were substantially protected from increases in mucosal TNF production and permeabil ity, and deletion of either gene markedly delayed onset of colitis 48 . Interestingly, claudin2 upregulation was also attenuated in MLCKdeficient mice 48 . Although the mice studied were generalized knockouts of the nonmuscle long MLCK, the ability of intestinal epi thelial CAMLCK expression to fully restore all features of disease (including claudin2 expression) in MLCK deficient mice indicates that the results are a specific effect of intestinal epithelial MLCK deletion 48 . These data indicate that both TNFR2 and MLCK inhibition might be appropriate targets for future biologic thera pies, and raise the possibility that TNFR2 blockade might have advantages over TNFtargeted biologic agents in terms of reduced overall immunosuppression and toxicity.
Intestinal barrier function and systemic disease. Increased intestinal permeability has been reported in patients with an array of autoimmune diseases, suggest ing a link between exposure to microbial antigens and development of autoimmune disease 103 . Most notable among these associations is the link between graft versus host disease (GVHD), which develops in many patients after allogeneic stem cell (bone marrow) transplant ation 174 . For many years it was known that the magni tude of intestinal barrier defects, primarily representing increased flux across the unrestricted pathway, corre lated with the severity of experimental GVHD 175, 176 . However, whether this finding merely represented the correlation between the extent of epithelial damage and GVHD severity or, alternatively, indicated that intes tinal barrier loss played a specific causative role, was unclear. One study 177 has shown that intestinal barrier loss is not required for the development of GVHD in the context of major antigen mismatchdriven bone marrow transplantation, which is the most commonly used experi mental model 47, 176, 177 . However, in the more clinically relevant setting of minor antigen mismatch transplantation, intestinal epithelial damage (that is, increased unrestricted pathway flux) was an essential cofactor in disease pathogenesis 177 . Remarkably, this requirement could be overcome by intraperitoneal delivery of lipopolysaccharide, suggesting that trans mucosal flux of bacterial products might be the key disease promoting event triggered by intestinal epithe lial damage 177 . The specific role of barrier loss mediated by tight junctions in GVHD has not yet been defined.
Decreased intestinal barrier function has also been noted before clinical disease onset in patients with type 1 diabetes mellitus 178 and in the biobreeding diabetes prone (BBDP) experimental rat model of type 1 diabe tes mellitus 179 . One study comparing the microbiota of BBDP rats to diabetesresistant (BBDR) rats has shown more abundant Lactobacillus and Bifidobacterium in the resistant rats [180] [181] [182] . However, whether alterations in microbiome composition are caused by diabetes or whether the alterations have a role in disease develop ment remains unknown. In another mouse model of diabetes (the nonobese diabetic mouse model), diabetes development can be influenced by exposure to, and ability to sense, luminal microbial stimuli 183, 184 . Owing to its role as the primary regulator of interaction between the immune system and luminal antigens, the epithelial barrier is likely to be essential in preventing diabetes development. Indeed, a pathogenic link between barrier dysfunction and diabetes has been proposed to work through the negative tight junction regulator zonulin, as zonulin expression is increased in BBDP rats and administration of antizonulin antibodies decreases autoantibody production and the development of clin ical type 1 diabetes mellitus in this model 185 . Although one study has reported that increased concentrations of serum zonulin correlate with intestinal permeability in patients with type I diabetes mellitus, a causative role of zonulin in patients has not been demonstrated 186 and this area of investigation remains controversial.
Targeting the epithelial barrier Targeting and restoring the epithelial barrier is a tempting therapeutic goal. Unfortunately, no thera pies currently exist to do so clinically, and one mol ecule (larazotide acetate) shown to restore epithelial barrier function in preclinical studies did not repli cate barrierprotective effects in clinical trials 140, 141, 187 . Nevertheless, many promising approaches to target the epithelial barrier have been proposed.
Epithelial barrier restoration. Engraftment of intes tinal stem cells has been proposed as a therapy for repairing damaged gastrointestinal mucosa (that is, the unrestricted pathway) 188, 189 . Technological advances have made longterm culture and expansion of intes tinal stem cells possible and have led many to believe that isolation, expansion and transplantation of intes tinal stem cells can aid in epithelial regeneration [190] [191] [192] . This idea is supported by one study in which mice were subjected to DSSinduced epithelial damage and given either a mock enema or enema with cultured intesti nal stem cells during recovery after DSS withdrawal 193 . Stem cells were able to engraft in areas of ulceration and serve as longlived intestinal stem cells in vivo. However, engraftment efficiency was low and resulted in minimal immediate improvement and no longterm improvement after removal of DSS, suggesting that the most effective way to restore the barrier is to remove the disease stimulus 193 . Moreover, the Lgr5 + intestinal stem cells that are expanded and engrafted have been proposed to serve as cancer stem cells 194, 195 , and care ful characterization of enteroid gene expression over many passages has not been performed, leaving open the possibility that engrafted enteroids might harbour malignant potential. Although detailed characterization and improved culture and engraftment methods might make this method more promising, without removal of the underlying stimulus causing epithelial damage (DSS in this case), this approach is unlikely to provide meaningful benefit.
More targeted approaches have also been pro posed and involve potentiating signalling pathways important for epithelial expansion 196, 197 . Two factors essential for the growth and expansion of intestinal stem cells -epidermal growth factor (EGF) and Rspondin1 -are possible therapeutic agents for restoring damaged epithelia. Activation of EGF recep tor protects against TNFinduced apoptosis of epithe lial cells 198 , and Rspondin1 reduces disease severity in epithelial damage models of colitis 199 . However, one might be cautious of this approach because both EGF and Rspondin1 are mitogens, and both EGF and the Rspondinaugmented Wnt pathway are dysregulated in colon cancer 200, 201 . For example, loss of a negative regu lator of the EGF pathway (LRIG1) results in hyper proliferation of intestinal epithelial cells in mice 202, 203 . However, one study indicated that EGF receptor sig nalling actually decreased colon cancer incidence and altered colonic cytokine production in IL10knockout colitic mice, supporting the potential of this approach in a subset of patients with colitis 204 .
Tight junction regulation. An alternative approach to barrier maintenance focuses on tight junction regulation and has potential in preventing initial IBD develop ment in susceptible individuals, and in promoting mainten ance of remission 47, 48 . As discussed, tight junction permeability is physiologically regulated to facilitate nutrient transport, raising concern of potential tox icity from this approach. Although further studies are necessary to characterize and miti gate these potential undesired effects, two targets are particularly enticing. One promising target is MLCK, which has a well defined mechanism of action with respect to barrier function in physiology and pathophysiology in vitro, in vivo and in patients with IBD 115 . Additionally, studies have shown beneficial effects of MLCK inhibition in mouse mod els of colitis when inhibition occurs specifically in the intestinal epithelium 48, 84 . However, MLCK inhib ition harbours potentially detrimental offtarget effects due to the fact that all MLCK isoforms share a common catalytic domain. For example, smooth muscle MLCK is essential for gastrointestinal motility, blood pressure regulation and airway contractility [205] [206] [207] . Although MLCK remains a promising target, more specific means of targeting long MLCK must be developed before consider ing MLCK as a drug target for treating human disease. Claudin2 also offers a potentially druggable target by either modulating claudin2 anchoring at the tight junction or directly targeting dynamic claudin2 pore opening and closing events 28, 30 . Unfortunately, no drug for claudin2 modulation currently exists.
Conclusions
Currently, the best therapy for treating epithelial barrier loss is to treat the underlying disease, as increased perme ability is as likely to be a consequence of the dis ease as it is to be a cause. For example, antiTNF anti bodies, which are successful therapies for IBD, treat the underlying immune activation while also markedly reducing intestinal permeability to near normal levels 78 .
Although targeting the epithelial barrier shows promise, more research is needed to define the mechanisms of epithelial homeostasis and disease pathogenesis before therapeutically targeting the epithelial barrier.
In terms of future directions, establishing or refut ing a pathogenic role for intestinal barrier dysfunction requires further investigation in both clinical stud ies and experimental models. Determining whether increased permeability in healthy firstdegree relatives of patients with Crohn's disease is a risk factor for dis ease development will also be important. Delineating the contributions of pore, leak and unrestricted path ways to observations of increased intestinal perme ability in both intestinal and systemic diseases will be necessary for mechanistic understanding of barrier function in disease, and subsequent rational therapeu tic design. Claudin2 and MLCK are potential thera peutic targets for modulation of tight junction pore and leak pathway permeability, respectively. However, developing the means to inhibit intestinal epithelial MLCK (to limit leak pathway flux increases) without toxicities due to systemic MLCK inhibition will be chal lenging. Likewise, modulating claudin2 pores (pore pathway) without negatively affecting overall epithe lial water and ion transport might also be complex. Tight junction proteins also have roles beyond barrier mainten ance, including epithelial morphogenesis and differentiation. Defining the underlying structurefunction relationships and their contributions to other physiological processes is a requisite precursor to tar geting barrier function without detrimental effects on other systems. If these goals can be achieved, the intes tinal barrier remains a promising therapeutic target in select disease states. 
